The C-terminal domain of G protein-coupled receptor kinases (GRKs) consists of a conserved region and a variable region, and the variable region has been shown to direct the membrane translocation of cytosolic enzymes. The present work has revealed that the C-terminal domain may also be involved in kinase-receptor interaction that is primarily mediated by the conserved region. Truncation of the C-terminal domain or deletion of the conserved region in this domain of GRK2 resulted in a complete loss of its ability to phosphorylate rhodopsin and in an obvious decrease in its sensitivity to receptor-mediated phosphorylation of a peptide substrate. On the contrary, deletion of the ␤␥ subunit binding region in the C-terminal domain of GRK2 did not significantly alter the ability of the enzyme to phosphorylate rhodopsin. In addition, the recombinant proteins that represent the C-terminal domain and the conserved region of GRK2 could inhibit GRK2-mediated phosphorylation of rhodopsin and receptor-mediated activation of GRK2 but not GRK2-mediated phosphorylation of the peptide substrate. Furthermore, the conserved region as well as the C-terminal domain could directly bind rhodopsin in vitro. These results indicate that the C-terminal domain, or more precisely, the conserved region of this domain, is important for enzymereceptor interaction and that this interaction is required for GRK2 to catalyze receptor phosphorylation.
G protein-coupled receptor kinases (GRKs) 1 form a family of serine/threonine protein kinases that phosphorylate specifically agonist-bound or -activated G protein-coupled receptors (1) . A common feature of this family is multi-site phosphorylation of receptor substrates in response to agonist occupancy (2) . GRK-mediated receptor phosphorylation promotes the binding of arrestin, thereby uncoupling the receptor from G proteins and terminating receptor signaling (1) . Based on sequence and functional similarities, the GRK family has been divided into three subfamilies: the rhodopsin kinase subfamily (RK or GRK1), the ␤-adrenergic receptor kinase subfamily (GRK2 and GRK3), and the GRK4 subfamily (GRK4, GRK5, and GRK6). Recently, a splice variant of human GRK1 (termed GRK1b) has been identified (3), and a candidate cone opsin kinase (termed GRK7) has been cloned from cone-and roddominant mammalian retinas (4) .
GRKs share a similar structural organization: a centrally located catalytic domain, an N-terminal domain, and a C-terminal domain. The N-terminal domains of GRKs, which are similar in size (ϳ185 amino acids), is believed to be responsible for receptor recognition. The C-terminal domains, which share a fair degree of structural homology but vary in length, can be divided further into two subdomains: a relatively conserved region and a variable region (1, 2) . The variable region in the C-terminal domain of GRKs contains the site of several posttranslational modifications and regulatory protein-protein interactions, which appear to be involved in the membrane and receptor targeting of GRKs (1, 2) . Different GRKs adopt different approaches to promote their membrane association, an event that is critical for receptor interaction. For example, the membrane localization of GRK2 and GRK3 is mediated by cooperative binding with the ␤␥ subunits of heterotrimeric G proteins and phosphatidylinositol 4,5-bisphosphate via their pleckstrin homology domains (5) (6) (7) (8) .
Recent studies have demonstrated that GRKs are subject to several modes of calcium-dependent regulation that provide the potential for feedback regulation and signaling cross-talk (9) . GRK1 activity in the visual system is inhibited by a Ca 2ϩ -binding protein, recoverin. Calcium binding to recoverin promotes its association with GRK1, which inactivates the kinase and thereby reduces its ability to phosphorylate rhodopsin (10 -12) . GRK2 and GRK5 are subject to regulatory phosphorylation via protein kinase C, a Ca 2ϩ /phospholipid-dependent kinase (13) (14) (15) . Calmodulin is also a potent inhibitor of GRK activity with the following selectivity: GRK5 (IC 50 ϳ 50 nM) Ͼ GRK6 Ͼ Ͼ GRK2 (IC 50 ϳ 2 M) Ͼ Ͼ GRK1 (16) .
Recent studies also suggest that GRKs may have more diverse protein-protein interactions within the cell (9) . It has been shown that the cytoskeletal protein tubulin binds to and is phosphorylated stoichiometrically by GRK2 and GRK5 (17) and that a specific interaction between GRKs and the integral membrane protein caveolin results in potent inhibition of GRK activity (18) .
The molecular mechanism by which GRKs specifically recognize and phosphorylate activated receptors and the roles of three domains of GRKs in GRK-mediated phosphorylation remain poorly understood. This study investigates the role of the C-terminal domain of GRK2 in receptor phosphorylation. Our results suggest that the conserved region within this C-termi-nal domain directly participates in the interaction with activated receptors, which is indispensable for receptor phosphorylation.
EXPERIMENTAL PROCEDURES

Construction of Expression Plasmids and Mutagenesis
The Escherichia coli expression plasmid of GRK2 was constructed by inserting the cDNA of bovine GRK2 (19) into pET 3a . The cDNA was amplified using standard polymerase chain reaction techniques, including the Expand TM High Fidelity PCR System (Roche Molecular Biochemicals). The amplified fragment with the introduced restriction sites was inserted into the expression vector pET 3a through the NdeI/ BamHI sites.
The C-terminal-truncated mutants of GRK2, N1 (1-457) and N2 (1-546), were engineered using standard polymerase chain reaction techniques by introducing a stop codon at the expected site. The mutant with 88 internal amino acids deleted (⌬CC, deletion of 458 -545) was constructed as follows: a 1.4-kilobase fragment encoding the N-terminal 457 amino acid residues (1-457) and a 0.6-kilobase fragment encoding the C-terminal 144 residues (546 -689) were amplified by polymerase chain reaction. Simultaneously, a new XbaI site with a silent mutation was introduced at both the 3Ј-end of the large fragment and the 5Ј-end of the small fragment. These two fragments were then ligated and cloned into the NdeI/BamHI-cleaved pET 3a .
The GST fusion proteins of the C-terminal domain (amino acids 457-689, termed C1), the G protein ␤␥ subunit binding region (amino acids 546 -689, termed C2), and the conserved region in the domain (amino acids 457-545, termed CC) of GRK2 were made by introducing the corresponding cDNA fragments into pGEX-4T-1 (Amersham Pharmacia Biotech) followed by expression in E. coli.
Protein Expression and Purification
Expression in E. coli and Purification of Bovine GRK2-Wild-type GRK2 was expressed in E. coli BL21(DE3) using the phage T7 RNA polymerase-based system described by Studier and Moffatt (20) . After isopropyl-1-thio-␤-D-galactopyranoside (10 M) induction at 22°C for 24 h in tyrptone-phosphate medium, proteins were extracted as described previously (21) with buffer containing 20 mM Tris-HCl, pH 8.0, 50 mM NaCl, 2 mM EDTA, 0.02% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 1 mM DTT, and 0.5 mg/ml lysozyme. The high speed supernatant of the extract from 1 liter of culture was loaded onto a Q-Sepharose FF column (2.5 ϫ 10 cm; Amersham Pharmacia Biotech), which was pre-equilibrated with Buffer A (20 mM Tris-HCl, pH 8.0, 50 mM NaCl, 2 mM EDTA, 0.02% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 1 mM DTT, 5% glycerol). GRK2 was not absorbed by Q-Sepharose and flowed through the column. The flow-through was pooled and applied to a Blue-Sepharose 4B (prepared in this laboratory) column (2 ϫ 8 cm) followed by washing with ϳ100 ml of 200 mM NaCl in Buffer A. GRK2 was then eluted with 1 M NaCl in Buffer A. The protein was concentrated by precipitation with 70% saturation of ammonium sulfate and chromatographed on an Ultrogel AcA34 column (2.5 ϫ 100 cm). The peak fractions were assayed by SDS-PAGE, and the fractions containing pure GRK2 protein were pooled and stored at Ϫ20°C in 50% glycerol. All the above purification steps were performed at 4°C.
Expression and Purification of Three Truncated Mutant Forms of GRK2-The three mutant proteins (N1, N2, and ⌬CC, see the schematic representation in Fig. 3A) were expressed under the same condition as that of the wild-type GRK2. N1 and N2 were purified to homogeneity by the same procedures used for the wild-type enzyme except that, at the final step, a Sephacryl S-200 (Amersham Pharmacia Biotech) column was used instead of the Ultrogel AcA34 column. ⌬CC was partially purified by using a Q-Sepharose FF column and a BlueSepharose column.
Expression and Purification of C1, C2, and CC Forms of GRK2-The expression plasmid for fusion protein was transformed into the E. coli strain DH12s and induced with isopropyl-1-thio-␤-D-galactopyranoside (0.1 mM) at 22°C for 16 h. The fusion proteins were purified by affinity absorption on GSH-Sepharose 4B (prepared in this laboratory) and eluted with 5 mM GSH as described (22) . Purified fusion proteins were dialyzed to remove GSH and incubated with thrombin in the ratio of 1:500 (w/w, thrombin/fusion protein) at 25°C for 1-3 h. GST tags were then removed using GSH-Sepharose beads.
Preparation of Urea-treated Rod Outer Segments and Truncated 329 G-Rhodopsin
Urea-treated rod outer segments (ROS) were prepared as described (23) . The prepared ROS showed negligible endogenous kinase activity and consisted of Ͼ80% rhodopsin as assessed by SDS-PAGE (data not shown). A truncated form of rhodopsin with 19 amino acid residues deleted from the C terminus ( 329 G-Rho) was made using endopeptidase Asp-N (Roche Molecular Biochemicals) cleavage as described (23, 24) . Complete conversion to 329 G-Rho was verified by SDS-PAGE, which showed a single protein band of 32 kDa that could not be phosphorylated by GRK2 (data not shown).
Assay of Phosphorylation of the Synthetic Peptides by GRK2
The peptide (RRREEEEESAAA) was synthesized by CyberSyn (Alston, PA). A stock peptide solution was prepared and adjusted to pH 7.4 with Tris base. Various concentrations of peptide (0 -1 mM) were incubated with GRK2 or its mutants (100 -400 ng), ␤␥ subunits (0 -200 nM, kindly provided by Dr. A. Smarka, University of Rochester, NY), 329 GRho* (0 -3 mM) in a buffer containing 20 mM Tris-HCl, pH 7.5, 2 mM EDTA, 7.5 mM MgCl 2 , 1 mM DTT, 0.5 mg/ml bovine serum albumin, and 0.1 mM [␥-
32 P]ATP (ϳ1 cpm/fmol; Amersham Pharmacia Biotech) in a final volume of 20 l at 30°C for 30 min or the indicated time and stopped by addition of 4 l of 60% trichloroacetic acid. The quenched reactions were centrifuged at 48,000 ϫ g for 10 min, and the resulting supernatants were transferred to a 2-ϫ 2-cm square of P81 paper (Whatman, Clifton, NJ) followed by five washes in 75 mM ice-cold phosphoric acid as described previously (25) . GRK2 activity was defined as the difference in phosphate incorporation in the presence and absence of peptide.
Assay of GRK2-mediated Rhodopsin Phosphorylation
Phosphorylation reactions contained, in a total volume of 20 l, urea-treated ROS (0 -10 M), ␤␥ subunits (0 -200 nM), and GRK2 (0 -200 ng) in 20 mM Tris-HCl, pH 7.5, 2 mM EDTA, 7.5 mM MgCl 2 , 1 mM DTT, and 0.1 mM [␥-
32 P]ATP (ϳ0.5 cpm/fmol). Reactions were bleached with light at 30°C for 1-3 min and stopped with 20 l of 2ϫ SDS sample buffer and electrophoresed on 10% SDS-polyacrylamide gels (26) . The 32 P-labeled receptor bands were quantified using a PhosphorImager (Molecular Dynamics) and excised and counted to determine the number, in picomoles, of phosphate incorporation.
Detection of Rho* Binding to GST-GRK2 Fusion Proteins
GRK2 C-terminal GST fusion proteins (5 g each) as described above were mixed, respectively, with 50 l of 50% slurry of GSH-Sepharose beads in the presence of 0.2% bovine serum albumin for 30 min at 4°C, then 5 g of the light-activated rhodopsin pretreated with 1% Triton X-100 was added and the mixture was incubated for another 2 h. After washed four to five times with buffer containing 20 mM Tris-HCl, pH 8.0, 50 mM KCl, 2 mM EDTA, and 0.01% Triton X-100, the beads were analyzed by Western blotting with an anti-rhodopsin antibody (Antihodopsin (opsin), RET-P1; Leinco Technologies Inc., Ballwin, MO) and SDS-PAGE, respectively, to detect retention of rhodopsin on the beads and amount of the GRK2 C-terminal GST fusion proteins.
RESULTS
Expression in E. coli, Purification, and Characterization of
Bovine GRK2-The bovine GRK2 was expressed in E. coli BL21 (DE3) using the phage T7 RNA polymerase-based system. The enzyme was purified from the cellular extract sequentially using Q-Sepharose FF, Blue-Sepharose 4B, and Ultrogel ACA-34 column chromatography as described under "Experimental Procedures." The enzyme was finally purified to homogeneity, as judged by SDS-PAGE (Fig. 1) . About 3 mg of GRK2 was obtained with an approximate yield of 30% from 1 liter of tryptone-phosphate medium.
Because it had never been described previously that GRKs were expressed heterologously in prokaryotic cells, doubts arose as to whether the property of GRK2 expressed in E. coli is similar to that expressed in eukaryotic cells. As shown in Fig.  2A , the enzyme expressed in E. coli specifically phosphorylated rhodopsin in a light-dependent fashion and the rate of the phosphorylation was markedly enhanced by about 10-fold by the addition of G protein ␤␥ subunits. The kinetic analysis revealed that the enzyme had a K m of 7.8 Ϯ 1.4 M and a maximal velocity of 447 Ϯ 33 nmol min Ϫ1 mg Ϫ1 for Rho* ( Table  I) . As reported previously, the K m and V max values were, respectively, 6 M and 72 nmol min Ϫ1 mg Ϫ1 for the enzyme puri-fied from bovine cerebral cortex (27) and were 14.5 M and 3017 nmol min Ϫ1 mg Ϫ1 for the enzyme expressed in Sf9 cells (28) . Previous studies have demonstrated that GRK2 preferentially phosphorylates peptides containing acidic residues on the Nterminal side of a serine or threonine, and the synthesized peptide RRREEEEESAAA was a good peptide substrate for GRK2 (23) . As shown in Fig. 2B , this peptide could be phosphorylated by the E. coli-expressed enzyme, and the phosphorylation was efficiently activated by 329 G-Rho*, a truncated form of Rho*. In addition, ␤␥ subunit itself did not affect the peptide phosphorylation but dramatically enhanced the 329 GRho*-activated peptide phosphorylation (Fig. 2B) . These results, consistent with the work of Kim et al. (29) and Chen et al. Effects of the C-terminal Truncations and Internal Deletion of C-terminal Domain on the Kinase Activity-As schematically represented in Fig. 3A, GRK2 consists of three domains, the N-terminal domain (amino acids 1-184), the central catalytic domain (amino acids 185-455), and the C-terminal domain (amino acids 456 -689). The C-terminal domain of GRKs is involved in membrane translocation of the enzymes (1). Much attention so far has been paid to the distinctive structure in the C-terminal domains of respective GRKs such as the CAAX motif in GRK1 that directs farnesylation (30, 31) , ␤␥ binding regions in GRK2 and GRK3 (5) (6) (7) (8) , and the palmitoylation sites in GRK4 (32) and GRK6 (33) . However, little heed was given to the region within the C-terminal domain that is rather conserved among the six GRK members (filled with slanted line in Fig. 3A) .
Identification of the ␤␥ subunit binding region was previously performed on GRK2, mainly by large fragment deletional mutagenesis (6, 34) . Kameyama et al. (34) reported that no kinase activity of two truncated mutants of GRK2, GRK2-563T and GRK2-590T (truncated amino acid residues from 563 or 590, respectively), was detected, and GRK2 562-632D (deleted amino acids of 562-632) was very labile, when expressed in COS-7 cells. Similarly, Koch et al. (6) reported that removing 57 or 127 amino acids from the C terminus of GRK2 (truncated amino acid residues from 563 or 633, respectively) significantly diminished the basal activity for phosphorylation of rhodopsin. This was presumably due to either protein misfolding or the failure of the interaction of the kinase with the receptor substrate.
In order to test whether the C-terminal domain of GRK2 plays an important role in the receptor phosphorylation, we first constructed the N1 mutant, which lacks the C-terminal domain (deleted amino acid residue from 458, Fig. 3A) . The N1 mutant was expressed in E. coli and purified to homogeneity as described above (Fig. 1) . The effect of deletion was then analyzed by examining the kinase activity of this mutant toward the peptide substrate as well as rhodopsin. Compared with wild-type GRK2, N1 had approximately 60% of the activity on synthesized peptide (Fig. 3C) , which suggested that deletion of the C-terminal domain had no significant effect on the activity of catalytic domain and the global conformation of the enzyme. However, as shown in Fig. 3B , N1 completely lost the ability to phosphorylate receptor Rho*, even when the mutant was used in excess amount (data not shown). On the other hand, N1 still could be activated by 329 G-Rho* in phosphorylating the peptide
FIG. 1. SDS-PAGE of the purified wild-type (WT), N1
, and N2 forms of GRK2. These three forms of GRK2 were purified to homogeneity, respectively, as described under "Experimental Procedures." Enzymes (1-3 g) were electrophoresed on a 12% gel and stained with Coomassie Blue R-250.
FIG. 2. Characterization of bovine GRK2 expressed in E. coli.
A, phosphorylation of rhodopsin by GRK2. The reactions were carried out by mixing 100 ng of purified GRK2 with 10 M rhodopsin, 0 or 200 nM ␤␥ subunits, 0.1 mM [␥-32 P]ATP (ϳ0.5 cpm/fmol), 20 mM Tris-HCl (pH 7.5), 7.5 mM MgCl 2 and 2 mM EDTA either in the light (ϩ) or dark (Ϫ) in a total volume of 20 l. The results were visualized using a PhosphorImager. B, synergistic activation of GRK2-mediated peptide phosphorylation by ␤␥ subunits and 329 G-Rho*. The synthetic peptide RRREEEEESAAA (1 mM) was incubated with 100 ng of GRK2 in a mixture containing 0 or 3 M 329 G-Rho*, 0 or 200 nM ␤␥, 20 mM Tris-HCl (pH 7.5), 2 mM EDTA, 7.5 mM MgCl 2 and 0.1 mM [␥-32 P]ATP (ϳ1 cpm/fmol) in a total reaction volume of 20 l. The reaction was quenched by spotting the sample on P-81 paper as described under "Experimental Procedures." Data points are the mean Ϯ range from two separate experiments done in duplicate. (Fig. 3D) but to a lesser extent (3-fold) than the wild-type GRK2 (14-fold). This suggests that the C-terminal domain contributes to the interaction between the enzyme and the receptor. Because the loss of the ability of N1 to phosphorylate Rho* is not due to the malfunction of the catalytic center, it is reasonable to hypothesize that the C-terminal domain is involved in the interaction with rhodopsin and that this interaction is required for receptor phosphorylation.
To further investigate which region in the C-terminal domain is responsible for the possible interaction with Rho*, two GRK2 mutants, N2 and ⌬CC, were constructed. As shown by the schematic presented in Fig. 3A, N2 retains the conserved region of the C-terminal domain (deleted amino acid residue from 547), whereas ⌬CC lacks the conserved region (deletion of 88 amino acid residues, 458 -545, within the C-terminal domain). N2 was also purified to homogeneity (Fig. 1) . But the purified form of ⌬CC was very susceptible to aggregation and precipitation (data not shown) so that partially purified ⌬CC was used instead.
The kinase activities of N2 and ⌬CC toward the peptide substrate were determined. Compared with the wild-type form, N2 has virtually the same activity, whereas ⌬CC has about 35% of the activity (Fig. 3C ). In addition, N2 was activated by 329 G-Rho* to the extent close to that of the wild-type enzyme, whereas the activated extent for ⌬CC was similar to that for N1 (Fig. 3D) . These results suggest that the two deletional mutants do not show significant changes in the conformations of their catalytic domains and/or the global conformations of the enzymes.
Unlike N1 and ⌬CC, N2, which contains the conserved region of the C-terminal domain, did catalyze the phosphorylation of rhodopsin (Fig. 3B ). In comparison with the wild-type enzyme, N2 had a higher K m and a slightly lower V max for rhodopsin (Table I) . Based on the results for the three forms (N1, N2, and ⌬CC) of GRK2, it was reasonable to postulate that the conserved region in the C-terminal domain of GRK2 is responsible for the possible interaction between the C-terminal domain and receptor. As expected, N2 was not stimulated by ␤␥ subunits (Fig. 3B) , because this mutant lacks the ␤␥ binding region.
Inhibitory Effects of the C-terminal Domain and the Conserved Region on GRK2
Activities-To further analyze the role of the C-terminal domain we used a novel approach. Three respective fragments, as schematically represented in Fig. 5A , containing the whole C-terminal domain (C1, amino acid residues 457-689), the sole ␤␥ subunit binding region (C2, amino acid residues 547-689), and the conserved region (CC, amino acid residues 457-546), respectively, were expressed as GST fusion proteins in E. coli. The fusion proteins were isolated by GSH-Sepharose affinity chromatography. C1, C2, and CC were separated from the GST and recovered as described (Fig. 4) . Their effects on wild-type GRK2 and N2 mutant-mediated phosphorylation were investigated. As shown in Fig. 5C , all three fragments showed little effect on the activity of the wildtype or N2-mediated phosphorylation of the peptide substrate. However, C1 and CC significantly inhibited the phosphorylation of rhodopsin by GRK2 or its N2 form. In the presence of 1 M C1 or CC, the activities of both the wild-type and N2 mutant were reduced to 40 -60%. As the concentration of C1 or CC rose to 5 M, only 10 -20% of the activity remained (Fig. 5B) . In contrast, C2 did not affect the activity of wild-type GRK2 or N2-mediated phosphorylation of rhodopsin. Similar results
FIG. 3. Analysis of GRK2 and its mutants.
A, schematic representation of the wild-type GRK2 (WT) and its mutants. B, phosphorylation of light-activated rhodopsin by the wild-type and mutant forms of GRK2. The reaction mixtures, which contained 5 M Rho*, 0 or 200 nM ␤␥ subunits, and 200 ng of each form of GRK2, were incubated for 3 min at 30°C. The amount of ⌬CC was estimated using SDS-PAGE and compared with that of the wild-type. control, the reaction was carried out in the absence of any forms of GRK2. The results were visualized (insert) and quantified using a PhosphorImager. The data show -fold magnitudes of the control, and the data points are the mean Ϯ range from two separate experiments done in duplicate. C, time courses of synthetic peptide phosphorylation by GRK2 and its mutants. Legends are described in Fig. 2B . 100 ng of each form of GRK2 was used. Data shown are the mean specific 32 P i incorporation values of at least two separate experiments. D, activation of the wild-type and mutants of GRK2 by 329 G-Rho*. 100 ng of each form of GRK2 was incubated without (Ϫ) or with (ϩ) 3 M light-activated 329 G-Rho in the reaction mixture, and the reaction was started by addition of 0.1 mM RRREEEEESAAA. Data shown were the mean Ϯ range from two separate experiments done in duplicate .   FIG. 4. SDS-PAGE of C1, C2, and CC forms of GRK2 . The fragments of the C-terminal domain (C1), the ␤␥ binding region (C2), and the conserved region (CC) were expressed, respectively, as GST fusion proteins and purified by affinity chromatography. The three fragments were separated from GST-tag by digestion with thrombin. GST was then removed by another affinity chromatography step. Lane 1, the purified GST-fused form of C1, C2, or CC; lane 2, the separate C1, C2, or CC with GST removed.
were also obtained by using GST-tagged C1, C2, and CC (data not shown). The negligible effect of C1 or CC on GRK2-mediated phosphorylation of the peptide suggested that the observed inhibitory effects of C1 or CC on the rhodopsin phosphorylation were probably due to their competitive binding to rhodopsin with GRK2.
In Vitro Binding of the C-terminal Domain or the Conserved Region of GRK2 with Rhodopsin-To investigate whether C1 or CC interacts with rhodopsin directly, the specific binding of the light-activated rhodopsin to the three GST fusion proteins (C1, C2, and CC) was examined by incubation of the activated receptor with C1 or CC bound to GSH-Sepharose beads. After extensive washing of the beads, retention of Rho* was analyzed by Western blotting with an anti-rhodopsin antibody. We found that C1 and CC, but not C2, could bind Rho* (Fig. 6) . The result clearly demonstrates that the C-terminal domain of GRK2 can interact with Rho* via its conserved region.
Based on all the findings in this work, we concluded that the interaction between this conserved region and receptor Rho* is essential for phosphorylation of the receptor by GRK2.
Effects of the Separate C-terminal Domain and the Conserved Region on the Receptor-activated Peptide Phosphorylation-As mentioned above, 329 G-Rho* activated N1 and N2 as well as the wild-type GRK2 on peptide phosphorylation (Fig. 3D) , and GRK2 mutants C1 or CC could bind rhodopsin (Fig. 6 ), which likely accounted for its inhibition of the GRK2-mediated receptor phosphorylation (Fig. 5B) . Based on these observations, C1 or CC should also have some effects on the receptor-activated peptide phosphorylation by GRK2. As shown in Fig. 7 , the 329 G-Rho*-mediated activation of the wild-type GRK2 and N2 mutant was greatly reduced by C1 as well as CC as expected. As a control, the C2 fragment does not have any effect on these enzymes (Fig. 7) . The activation of wild-type GRK2 or its N2 form was reduced to 13-19% in the presence of 5 M of C1 or CC. However, GRK2 N1, which lacks the whole C-terminal domain, was not affected by any of three fragments (Fig. 7) . The results indicate that the interaction between C1 or CC and rhodopsin is highly site-specific and that the GRK2 mutants C1 and CC interfere with the interaction between the wild-type/N2 mutant GRK2 and rhodopsin. DISCUSSION It has long been known that the C-terminal domain of GRK2 plays an important role in the translocation of the cytosolic enzyme to the membrane (5) . In this work we unraveled a novel function of this domain in receptor phosphorylation. Here different approaches were employed, including C-terminal dele- FIG. 6 . Direct binding of the GST-fused C-terminal domains of GRK2 with Rho*. GST-C1, GST-C2, and GST-CC fusion proteins were purified as described under "Experimental Procedures." 5 g of Rho* was added to 50 l of GSH-Sepharose beads, which bound approximately 5 g of each GST fusion protein. After washing three times, one-third of the beads were analyzed by Western blotting using antirhodopsin antibody (upper panel), and one-third of the beads were used to detect the amount of the fusion proteins by SDS-PAGE (lower panel).
FIG. 7. Effect of the separate C-terminal domain on the activation of GRK2 by
329
G-Rho*. Each of the purified C1, C2, and CC forms, at concentration of 5 M, was mixed with 3 M 329 G-Rho* and incubated briefly at room temperature. Then each form of GRK2 (100 ng each) was added. The reaction was initiated by addition of 0.1 mM peptide. The 32 P incorporation was determined as described under "Experimental Procedures." Data shown are the mean Ϯ range from two separate experiments done in duplicate.
FIG. 5. Effects of C1, C2
, and CC on GRK2-mediated phosphorylation of rhodopsin and peptide substrate. A, schematic representation of C1, C2, and CC forms of GRK2. B, effects of C1, C2, and CC on Rho* phosphorylation by WT or N2 form of GRK2. C1, C2, or CC at the indicated concentrations (1 and 5 M, respectively) was mixed with 5 M Rho*, and the reaction was started by addition of 100 ng of WT or the N2 form enzyme and incubated at 30°C for 3 min. The results were quantified using a PhosphorImager. The data show the percentage of control, which represent the means Ϯ S.E. for three separate experiments done in duplicate. C, effects of C1, C2, and CC on phosphorylation of peptide substrate by WT or N2. Peptide (0.1 mM) was used in the reaction. The reaction mixtures were incubated for 30 min at 30°C. The data represent the means Ϯ S.E. for three separate experiments done in duplicate.
tional mutagenesis, analysis of effects of the separate C-terminal domain on the function of GRK2, and in vitro testing of binding of the C-terminal domain with the receptor. Our experiments, with purified proteins, also minimized the potential interferences from other factors involved in the kinase-receptor interaction. Our data clearly demonstrated: 1) Truncation of the C-terminal domain of GRK2 resulted in a complete loss of its ability to phosphorylate the receptor and significant impairment of its sensitivity to the receptor-mediated activation of peptide phosphorylation (Fig. 3, B and D) ; 2) The GRK2 mutant C1, which encompasses the C-terminal domain, inhibited GRK2-mediated phosphorylation of rhodopsin but did not inhibit GRK2-mediated phosphorylation of the peptide substrate (Fig. 5); 3) The activation of GRK2 by 329 G-Rho* was greatly diminished by the C-terminal domain fragment (Fig. 7) ; and 4) Rhodopsin was specifically coprecipitated with the GST-tagged C-terminal domain (Fig. 6) . These results indicate that the C-terminal domain of GRK2 is involved in enzyme-receptor interaction and that this interaction is necessary for GRK2 to catalyze receptor phosphorylation.
Previous work had focused on the distal region of the Cterminal domain, which has little homology among different GRK members and was involved in receptor targeting and membrane association (1, 2) . The proximal region of this domain is rather conserved and includes a proline-rich motif (PPXXP) and putative sites for kinase autophosphorylation (2) . Beyond this, little had been known about this conserved region until recently when Yu et al. (35) reported that GRK1, with deletion of the C-terminal 39 amino acid residues (which included part of the conserved region), lost its ability to phosphorylate rhodopsin but retained its ability to phosphorylate peptides. Our current work on GRK2 revealed that this conserved region is important for enzyme-receptor interaction, which was required for phosphorylating receptor by GRK2. This was demonstrated by the results derived from the three C-terminal domain deletional mutants. Among these mutants only N2 retained its ability to phosphorylate rhodopsin (Fig. 3B) . N2 is the only one that includes the conserved region. In addition, the conserved region (CC) rather than the ␤␥ binding region (C2) inhibits the activity of GRK2 for rhodopsin (Fig. 5B) and 329 GRho*-mediated activation of GRK2 (Fig. 7) , and CC rather than C2 could bind with rhodopsin in vitro (Fig. 6) .
Koch et al. (6) reported that the ␤␥ activation of GRK2 was inhibited by a GRK2 C-terminal GST fusion protein (protein I, residues 467-689) and a 28-mer peptide corresponding to residues 643-670 (peptide G). Protein I encompasses the conserved region and the ␤␥ binding region, and peptide G corresponds to the last 28 amino acids of the ␤␥ binding region. They observed that the inhibitory potency of protein I was one order of magnitude greater than peptide G (IC 50 of 7.7 and 76 M, respectively) (6) . In connection with the data presented in our study, we believe that the much stronger inhibitory effect of protein I was caused by its competitive binding to the receptor with GRK2 through the conserved region.
The conservation of the region in the C-terminal domain adjacent to the catalytic domain suggests that this region possesses conserved functions among GRK members. One of the functions, as we have demonstrated, may be the involvement in the GRK2-rhodopsin interaction. It remains to be determined whether the same region is critically involved in the functional interaction of other GRKs and receptors. Such investigation is underway in our laboratory.
